Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Zhonghua Yu Fang Yi Xue Za Zhi ; 57(11): 1843-1847, 2023 Nov 06.
Artigo em Chinês | MEDLINE | ID: mdl-38008575

RESUMO

This study systematically retrieved information on the payment policy of vaccination fees for pneumococcal vaccines, human papillomavirus vaccines, haemophilus influenzae type b vaccines and rotavirus vaccines using a Python-based crawler. The proportion of the population covered by policies among the total applicable population was estimated based on the medical insurance coverage ratio and population data in 2020. This study showed that the payment policies included two categories, government-funded free vaccination policies and medical insurance payment policies. Among the four non-national immunization program vaccines, the free vaccination policies only involved pneumococcal vaccines and human papillomavirus vaccines. Among them, the 13-valent pneumococcal conjugate vaccine, the 23-valent pneumococcal polysaccharide vaccine, and the human papillomavirus vaccine were provided free of charge in 1, 10 and 15 provinces, respectively. For these policies, the corresponding covered population and the proportion among the total applicable population were children aged 6 months to 2 years old (2.5%), older people (1.2% to 21.5%) and middle school girls (1.1% to 12.2%). Medical insurance payment policies were implemented in 14 provinces, and nearly covered the four types of vaccines in the policy implementation areas, with the proportion of the covered population about 10.9% to 41.5% among the total applicable population.


Assuntos
Vacinas contra Papillomavirus , Vacinas Pneumocócicas , Criança , Feminino , Humanos , Lactente , Idoso , Vacinação , Políticas , Programas de Imunização , China , Vacinas Conjugadas
2.
Eur Rev Med Pharmacol Sci ; 23(12): 5260-5269, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31298377

RESUMO

OBJECTIVE: This study aims to investigate the expression of microRNA (miR)-16 in non-small cell lung carcinoma (NSCLC) and to identify its potential mechanism. PATIENTS AND METHODS: A total of 45 NSCLC patients were included in the present work. NSCLC tissues and adjacent normal tissues were resected and collected. The Reverse Transcription-quantitative Polymerase Chain Reaction was used to determine miR-16 expression. Regulatory effects of miR-16 on proliferation, migration and invasion, and cell cycle of A549 cells were determined by Cell-Counting Kit 8 assay, transwell assay, and flow cytometry, respectively. Western blotting was performed to measure the protein expression of matrix metalloproteinase (MMP)-19 in cells overexpressing miR-16. Dual-luciferase reporter gene assay was conducted to identify the interaction between miR-16 and MMP-19. RESULTS: MiR-16 expression in NSCLC significantly decreased compared with that in healthy tissue (p<0.05). The expression level of miR-16 was negatively correlated to the clinical staging of NSCLC. In addition, the expression of miR-16 in NSCLC patients with lymph node metastasis was significantly lower than that in patients without lymph node metastasis (p<0.05). In vitro studies demonstrated that miR-16 inhibited the proliferation, migration, and invasion of A549 cells. Western blotting analyses indicated that overexpression of miR-16 down-regulated the expression of MMP-19. Additionally, the dual-luciferase reporter gene assay determined that miR-16 directly regulated the expression of MMP-16. CONCLUSIONS: The present study demonstrates that miR-16 acts as a tumor-suppressor gene by inhibiting the proliferation, migration, and invasion of NSCLC cells via downregulating MMP-19 expression.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/genética , Regulação Neoplásica da Expressão Gênica , Neoplasias Pulmonares/genética , Metaloproteinases da Matriz Secretadas/genética , MicroRNAs/metabolismo , Células A549 , Adulto , Idoso , Carcinoma Pulmonar de Células não Pequenas/patologia , Carcinoma Pulmonar de Células não Pequenas/cirurgia , Ciclo Celular , Movimento Celular/genética , Proliferação de Células/genética , Regulação para Baixo , Feminino , Genes Supressores de Tumor , Humanos , Pulmão/patologia , Pulmão/cirurgia , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/cirurgia , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica/genética , Pneumonectomia , Adulto Jovem
3.
Genet Mol Res ; 11(4): 3618-28, 2012 Oct 04.
Artigo em Inglês | MEDLINE | ID: mdl-23096687

RESUMO

Epidemiological studies of the association of variants p53 Arg72Pro and MDM2 single-nucleotide polymorphism 309 (SNP309) with glioma risk have produced inconsistent results. The aim of the current study was to evaluate the association of these 2 variants with glioma susceptibility using a meta-analysis approach. For p53 Arg72Pro, 10 case-control studies including 2587 glioma patients and 4061 unrelated controls were identified. The pooled odds ratios (ORs) for Arg/Pro heterozygotes and Pro/Pro homozygotes were 1.08 [95% confidence interval (95%CI) = 0.85-1.37] and 1.08 (95%CI = 0.85-1.36), respectively, when compared to Arg/Arg carriers. Under the dominant effect model, Pro allele carriers also showed no significantly elevated glioma risk (pooled OR = 1.11, 95%CI = 0.90-1.38), and similar results were found under the recessive-effect model (pooled OR = 1.17, 95%CI = 0.85-1.61). For variant MDM2 SNP309, 3 case-control studies including 606 cases and 309 controls were identified. A marginal association with glioma risk was found for heterozygous G/T carriers (pooled OR = 1.95, 95%CI = 1.00- 3.81), whereas homozygous G/G carriers showed an increased but not significantly elevated risk of glioma (pooled OR = 2.14, 95%CI = 0.71-6.45) compared with that of T/T homozygotes. We also found no significant association between the MDM2 SNP309 polymorphism and glioma risk (pooled OR = 1.86, 95%CI = 0.94-3.67 and pooled OR = 1.25, 95%CI = 0.62-2.56, respectively) under the dominant and recessive models. Taken together, the current data suggested that the 2 polymorphisms may not contribute to glioma susceptibility.


Assuntos
Neoplasias Encefálicas/genética , Estudos de Associação Genética , Predisposição Genética para Doença , Glioma/genética , Polimorfismo de Nucleotídeo Único/genética , Proteínas Proto-Oncogênicas c-mdm2/genética , Proteína Supressora de Tumor p53/genética , Neoplasias Colorretais/genética , Heterozigoto , Humanos , Fatores de Risco
4.
Virology ; 365(1): 166-72, 2007 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-17467767

RESUMO

Porcine epidemic diarrhea virus (PEDV) causes lethal diarrhea in piglets that leads to great economic losses in East Asia. It was reported that aminopeptidase N (APN) is the receptor for transmissible gastroenteritis virus (TGEV), human coronavirus 229E (HCoV-229E) and feline coronavirus (FeCoV) which all belong to group I coronavirus including as well as PEDV. It was also confirmed previously that porcine aminopeptidase N (pAPN) can bind to PEDV, and anti-pAPN antibodies may inhibit the combination. To investigate whether pAPN is a receptor for PEDV, we transfected MDCK cells with porcine aminopeptidase (pAPN) cDNA and this enabled non-susceptible cells to support PEDV replication and serial viral propagation. Moreover, the infection was blocked by antibodies against pAPN, implies the critical role of pAPN during virus entry. In addition, immunofluorescence assays for detection of pAPN and PEDV antigens, together with neutralization assays using antibodies against pAPN, further confirmed the correlation between pAPN expression and viral replication in pAPN-transfected MDCK cells. These results indicate that pAPN is a functional receptor for PEDV.


Assuntos
Antígenos CD13/metabolismo , Infecções por Coronavirus/veterinária , Vírus da Diarreia Epidêmica Suína/fisiologia , Receptores Virais/metabolismo , Doenças dos Suínos/virologia , Animais , Anticorpos Antivirais , Linhagem Celular Transformada , Chlorocebus aethiops , Infecções por Coronavirus/virologia , Vírus da Diarreia Epidêmica Suína/enzimologia , Receptores Virais/genética , Suínos , Doenças dos Suínos/metabolismo , Células Vero
5.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 15(3): 165-7, 1995 Mar.
Artigo em Chinês | MEDLINE | ID: mdl-7647534

RESUMO

The cerebral ischemia rabbit model was made by using the occlusion of four vessels. The results showed that TXB2 and cAMP contents in brain tissues and the latter in plasma markedly increased (P < 0.05, P < 0.01), the 6-keto-PGF1 alpha in brain tissues significantly lowered (P < 0.05) in ischemia formed 30 minutes and 45 minutes after reperfusion. After intravenous injection of Astragalus membranaceus (AM) extracts (3.3 g/kg), Huoxuefang (HXFO and Yiqi Houxue Fang (YQHXF) consisted of AM and HXF before ischemia, the marked increase of TXB2 contents after reperfusion was inhibited (P < 0.05) and the 6-keto-PGF1 alpha in brain tissues after reperfusion were increased (P < 0.01) in HXF and YQHXF group, which change the AM extracts didn't have (P < 0.05). HXF could markedly inhibit the increase of cAMP in brain tissues after reperfusion P < 0.05), while the AM extracts and YQHXF couldn't (P > 0.05). All above-mentioned suggested that the above-mentioned suggested that the balance disorder of TXA2/PGI2 in brain tissues might participate in the occurrence of cerebral reperfusion injury and YQHXF might act against this injury by means of improving the balance of TXA2/PGI2 in brain tissues, which was mainly released by HX drugs of it.


Assuntos
Isquemia Encefálica/complicações , Encéfalo/metabolismo , Medicamentos de Ervas Chinesas/farmacologia , Traumatismo por Reperfusão/metabolismo , Tromboxano B2/metabolismo , 6-Cetoprostaglandina F1 alfa/metabolismo , Animais , Astragalus propinquus , AMP Cíclico/sangue , Feminino , Masculino , Coelhos
6.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 13(11): 652-4, 643, 1993 Nov.
Artigo em Chinês | MEDLINE | ID: mdl-8155938

RESUMO

Malondialdehyde (MDA) and 6-keto-PGF1 alpha levels in plasma and erythrocyte superoxide dismutase activities (Ery-SODA) were observed in 56 cases of thromboangiitis obliterans (TAO). The results showed that: (1) Ery-SODA and 6-keto-PGF1 alpha levels lowered and MDA raised significantly in TAO (P < 0.01), compared with that in control. (2) 6-keto-PGF1 alpha levels were markedly related with Ery-SODA and MDA in TAO (P < 0.01). (3) Ery-SODA and 6-keto-PGF1 alpha levels were lower and MDA higher in III phase of TAO than that in II phase. (4) Ery-SODA and 6-keto-PGF1 alpha levels markedly declined and MDA contents elevated significantly in Dampness-Heat (DH) and Heat-Toxin (HT) group, compared with that in Yin-Cold (YC) group and Blood-Stasis (BS) group, respectively (P < 0.05, P < 0.01); all above substances between YC and BS group or between DH and HT group had no significant differences (P > 0.05). (5) Ery-SODA and 6-keto-PGF1 alpha levels were lower and MDA higher in Heat Syndrome than that in Cold Syndrome (P < 0.01). It suggested that oxygen free radical and lipid peroxide response that might participate in vascular endothelial cell injury in TAO markedly increased and the detection of these substances might provide complementary evidences for syndrome differentiation of TAO.


Assuntos
Epoprostenol/metabolismo , Medicina Tradicional Chinesa , Tromboangiite Obliterante/metabolismo , 6-Cetoprostaglandina F1 alfa/sangue , Adulto , Diagnóstico Diferencial , Radicais Livres , Humanos , Masculino , Malondialdeído/sangue , Superóxido Dismutase/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...